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Abstract 
Background: Pancreatic cancer stem cells (CSCs) are responsible for resistance to standard therapy, 
metastatic potential, and disease relapse following treatments. The current therapy for pancreatic 
ductal adenocarcinoma (PDAC) preferentially targets the more differentiated cancer cell population, 
leaving CSCs as a cell source for tumor mass formation and recurrence. For this reason, there is an 
urgent need to improve current therapies and develop novel CSC-targeted therapeutic approaches.  
Methods: Hyaluronic acid (HA) decorated liposomes, containing diethyldithiocarbamate-copper 
(Cu(DDC)2), able to target the specific CSC marker CD44 receptor were prepared by ion gradient 
technique and fully characterized. Their antiproliferative effect was evaluated on pancreatic CSCs 
derived from PDAC cell lines or patients. To clarify the mechanism of action of Cu(DDC)2 
liposomes, ROS level neutralization assay in the presence of N-acetyl-L-cysteine was performed. 
Results: Liposomes showed high encapsulation efficiency and Cryo-TEM analysis revealed the 
presence of Cu(DDC)2 crystals in the aqueous core of liposomes. In vitro test on pancreatic CSCs 
derived from PDAC cell lines or patients showed high ROS mediated anticancer activity of HA 
decorated liposomes. The sphere formation capability of CSCs obtained from patients was 
drastically reduced by liposomal formulations containing Cu(DDC)2. 
Conclusions: The obtained results show that the encapsulation of Cu(DDC)2 complex in HA 
decorated liposomes strongly increases its anti-proliferative activity on pancreatic CSCs. 
General significance: This paper describes for the first time the use of HA decorated liposomes 
containing Cu(DDC)2 against pancreatic CSCs and opens the way to the development of 
nanomedicine based CSC-targeted therapeutic approaches. 
 
Keywords: liposomes; hyaluronic acid; diethyldithiocarbamate/copper complex; CD44; pancreatic 
cancer stem cells; PDAC patient-derived cells. 
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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease that is frequently diagnosed at 
a late stage and represents the fourth leading cause of cancer-related deaths in the modern world 
with a five-year survival rate around 5–7% [1, 2]. In the clinic, the present therapies rarely reduce 
tumor size and counteract tumor reappearance, thus rendering the identification of new therapeutic 
strategies necessary.  
A growing body of evidence suggests that PDAC initiation, growth, metastasis and resistance to 
therapy are driven by a small population of cells, called cancer stem cells (CSCs) or tumor initiating 
cells [3-5]. Pancreatic CSCs were identified in 2007 by Li et al [3], who showed that pancreatic 
cancer cells with the CD44
+
/CD24
+
/ESA
+
 phenotype (0.2–0.8% of all pancreatic cancer cells) 
possessed a 100-fold increased tumorigenic potential compared with marker negative cancer cells 
and just a small fraction of CD44
+
/CD24
+
/ESA
+
 cells was sufficient to give rise to tumors 
histologically indistinguishable from the primary human tumor. After this discovery, great efforts 
have been made to understand the CSC biology in terms of origin and propagation, and their role in 
cancer progression and metastasis promotion. CSC population shows specific features, including 
the ability to self-renew, to produce a more differentiated progeny, to grow in independent 
anchorage conditions, and to resist to standard chemotherapy engendering disease relapse following 
treatment [4, 6]. In the context of chemoresistance and recurrence, a major impact on tumor 
progression can derive from the use of treatments directed against not only differentiated cells, that 
represent the bulk of the tumor, but also CSCs [7]. Thus, in order to develop CSC-targeted 
therapies, it is important to take advantage of CSC specific features, that in part have already been 
identified, and of in vitro cell cultures and patient-derived xenograft models [8, 9] that represent the 
tumor heterogeneity of PDAC. For instance, a frequent strategy used in this field has been the 
targeting of CD44-expressing CSCs with its specific ligand, hyaluronic acid (HA) [10, 11]. 
The anti-alcoholism drug disulfiram (DSF, Antabuse
®
) has been shown to act as antitumoral drug 
[12-21] and represents a possible candidate as an anti-CSC agent in breast cancer and glioblastoma 
[22, 23]. The anticancer activity of DSF has not yet been fully elucidated. Indeed, several 
mechanisms have been proposed, such as the inhibition of aldehyde dehydrogenase, proteasome, 
NF-κB, DNA methyltransferase, and multidrug resistance p-glycoprotein activities [13, 23-27]. 
Furthermore, when used in combination with copper, DSF becomes a strong inducer of radical 
oxygen species (ROS) [27-30]. Despite its powerful anticancer activity, the development of DSF-
based cancer therapy has been hampered by its poor solubility in biological fluid and instability in 
gastric juice and bloodstream [31]. To overcome these limitations, the development of drug delivery 
systems is crucial in order to protect DSF from degradation and increase drug concentration in 
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tumor site [32]. Moreover, the encapsulation of DSF into nanoparticles renders it suitable for 
intravenous administration. One of the most known drug delivery system is liposomes, which, 
because of their structure, can encapsulate a wide range of molecules with hydrophilic, amphiphilic, 
or lipophilic characteristics. In addition, the phospholipidic framework ensures complete 
biocompatibility [33]. Along the years, the research in liposome field has been gradually oriented 
towards the development of systems capable of specifically recognizing the target cells [34]. This 
strategy, known as active targeting, involves the use of a targeting agent able to “drive” the 
nanosystem directly on the target cells by recognition of specific molecules overexpressed on cell 
surface. According to this strategy, different liposomes decorated with antibodies, peptides, small 
molecules, or aptamers have been developed and have shown a significant improvement in tumor 
drug accumulation [35-38]. 
In this work, we designed liposomes containing DSF or diethyldithiocarbamate-copper complex 
Cu(DDC)2 in order to obtain a nanotechnology platform able to selectively target and destroy 
pancreatic CSCs. This study is basically divided in two parts. The first concerns the preparation and 
characterization of liposomal formulations containing DSF and Cu(DDC)2 either plain or targeted, 
thus selective for pancreatic CSCs. For the active targeting strategy, HA was chosen as targeting 
agent because pancreatic cancer cell lines, such as Panc1 cells, and CSCs have been shown to 
display an over-expression of its receptor, CD44 [39]. Moreover, HA is a biodegradable, non 
immunogenic and non toxic polymer, features that make it a good candidate as a targeting agent 
[40, 41]. In order to obtain liposomes decorated with HA, conjugates between the phospholipid 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and HA were synthesized and incorporated 
in the liposomal preparations. HA of low molecular weight (MW) (4,800 and 17,000 Da) were 
chosen as targeting agents on the basis of our previous work that demonstrated a strong affinity of 
the oligomers towards CD44
 
positive pancreatic tumor cells [42, 43]. The second part of the study 
concerns the in vitro evaluation of the effect of DSF and Cu(DDC)2 liposome formulations on 
proliferation of CSCs derived from PDAC cell lines or patients and the analysis of ROS to define 
the differential activity of the formulations on parental cells and CSCs.  
2. Material and methods 
 
2.1. Materials and instruments 
 
Sodium hyaluronate of MW 4,800 (HA4800) and 17,000 (HA17000) Da were purchased from Lifecore 
Biomedical (Chaska, MN). All the phospholipids were provided by Avanti Polar-Lipids distributed 
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by Spectra 2000 (Rome, Italy). Solvents, N-acetyl-L-cysteine (NAC), diacetylated 2′,7′-
dichlorofluorescein (DCF-DA) probe and all the other chemicals were obtained from Sigma-
Aldrich (Milan, Italy). 
HPLC analyses were carried out using a Merck Hitachi HPLC System (Milan, Italy). The analytical 
column was a Symmetry C18 column, 5 µm (Merck) equipped with a C18 column guard (Merck 
Hitachi HPLC) system. Spectrophotometric analyses were performed using Beckman Coulter DU 
730 UV-vis spectrophotometer. Mass spectrometry analyses (MS) were carried out using 
electrospray ionization (ESI) or by atmospheric pressure chemical ionization (APCI), in positive ion 
mode, on a Micromass ZQ spectrometer (Waters). The 
1
H nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker 300 Ultrashield instrument (Karlsruhe, Germany) in a mixture of 
D2O, CD3OD, CF3CO2D in a volume ratio of 6:3:1 at room temperature, with Me4Si (TMS) as 
internal standard. Differential scanning calorimetry (DSC) was performed using a DSC Q1000 (TA 
Instruments). CryoTEM was performed at I2BC (Gif-sur-Yvette, France) using a JEOL JEM-1400 
operating at 120 kV. Images were recorded on a US1000XP camera (Gatan Inc, CA) with a -4.2 µm 
defocus. The reactions were monitored by thin-layer chromatography (TLC) on F245 silica gel 
precoated sheets (Merck).  
 
2.2. Synthesis and characterization of hyaluronic acid-phospholipid conjugates 
 
HA-DPPE conjugates were prepared using the method described by Arpicco et al [42]. A minor 
modification was introduced in the purification process: to completely eliminate the unreacted 
phospholipid still present in the conjugate after dialysis, extraction process with dichloromethane 
was performed. In this way, the unreacted DPPE was solubilised in the organic phase and thus 
separated from the conjugate. The aqueous phase was analyzed by TLC (chloroform/methanol 
70:30 v/v) to monitor the disappearance of free DPPE from the conjugate and the extraction with 
dichloromethane was repeated until complete removal of the free phospholipid. The purified 
compounds were freeze-dried, and the yield was 30% for HA4800-DPPE conjugate and 60% for 
HA17000-DPPEconjugate. 
1
H NMR (D2O, CD3OD, CF3CO2D in a volume ratio of 6:3:1, 300 MHz): 
d 0.9 (6 H, terminal CH3 of DPPE), 1.3 (56 H, methylene protons of DPPE), 1.5 (4 H, NHCH2CH2), 
2.0 (Nac-CH3), 3.3–4.0 (sugar ring protons), 4.4–4.6 (sugar ring protons). 
 
2.3. Preparation of DDC/metal complexes 
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DDC/metal complexes were synthesized by adding dropwise MilliQ
®
 water solution of CuCl2 2H2O 
(75.53 mg, 0.443 mmol; Cu(DDC)2) or FeCl3 6H2O (119.74 mg, 0.443 mmol; Fe(DDC)2) or ZnSO4 
H2O (79.50 mg, 0.443 mmol; Zn(DDC)2) to MilliQ
®
 water solution of DSF active metabolite 
sodium diethyldithiocarbamate trihydrate (DDC, 100 mg, 0.443 mmol). The reaction was stirred at 
room temperature for about 10 minutes until the formation of precipitate, which indicates the 
occurred complexation. The solution was then filtered and the resulting precipitate was washed 
three times with MilliQ
®
 water and dried under vacuum. The formation of the DDC/metal 
complexes was assessed by MS. Cu(DDC)2: (C10H20CuN2S4) calc: 358.98, found: 359.13 [M]
+
, 
Fe(DDC)2: (C10H20FeN2S4) calc: 351.99, found: 352.15 [M]
+
, Zn(DDC)2: (C10H20ZnN2S4) calc: 
359.98, found: 360.14 [M]
+
. 
 
2.4. Preparation of liposomes 
 
2.4.1. DSF containing liposomes 
DSF containing liposomes (LipoDSF-5%PEG) were prepared using the thin lipid film-hydration 
method mixing together 1,2-distearoil-sn-glycero-3-phosphocoline (DSPC), cholesterol (CHOL) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] 
(mPEG2000-DSPE) in 55:40:5 molar ratio. DSF was added to the lipid mixture in 14% ratio (mol 
drug/mol lipid). The resulting lipid film was hydrated with 900 µl of citric acid buffer (pH 4.8), as 
DSF is more stable at pH value of 4.5-5 [44]. The suspension was vortex mixed for 10 min and bath 
sonicated. The formulations were extruded (Extruder, Lipex, Vancouver, Canada) at 60 °C under 
nitrogen through 200 nm polycarbonate membrane (Costar, Corning Incorporated, NY) and then 
purified by gel filtration using Sepharose CL-4B columns, eluting with HEPES buffer. Liposomes 
were stored at 4 °C. 
 
2.4.2. Cu(DDC)2 containing liposomes 
Liposomes (LipoCu(DDC)2-5%PEG) were prepared using a method recently described by Wehbe 
et al. [45] with minor modifications. The liposomes were composed of DSPC, CHOL and 
mPEG2000-DSPE in 55:40:5 molar ratio. Lipids were dissolved in chloroform and evaporated by 
rotary evaporator. The resulting lipid film was hydrated with 1 ml of CuCl2 solution (300 mM), 
vortex mixed and incubated for one hour at 60 °C. Liposomes were then extruded as previously 
reported and purified from unencapsulated CuCl2 through chromatography on Sepharose CL-4B 
columns, eluting with SHE buffer [sucrose (300 mM), HEPES (20 mM) and EDTA (15 mM)] (pH 
7.5). Then, a solution of DDC (0.25 mg/50 µl MilliQ
®
 water) was added to liposomes and incubated 
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for 25 minutes at room temperature. Finally, liposomal preparations were purified from 
unencapsulated Cu(DDC)2 through chromatography on Sepharose CL-4B columns, eluting with SH 
buffer [sucrose (300 mM) and HEPES (20 mM)] (pH 7.5). Liposomes were stored at 4 °C.  
To prepare HA liposomes (LipoCu(DDC)2-5%HA4800, LipoCu(DDC)2-5%HA17000, LipoCu(DDC)2-
2%PEG-3%HA4800, and LipoCu(DDC)2-2%PEG-3%HA17000), the same method was used. Lipid 
films were made up of DSPC/CHOL/mPEG2000-DSPE (55:40:2 molar ratio) or DSPC/CHOL 
(55:40 molar ratio) and then hydrated using CuCl2 solution of the different HA-DPPE conjugates (3 
or 5 molar ratio). 
 
2.5. Liposomes characterization 
 
The mean particle size and polydispersity index (PDI) of the liposomes were determined at 20 °C 
by dynamic light scattering using a Zetasizer (Nano-ZS, Malvern instruments, UK). Size 
measurements were performed at a fixed angle of 173° after dilution of the liposome suspensions in 
MilliQ
®
 water. Each measurement was carried out in triplicate. The surface charge of liposomes 
was evaluated by zeta potential measurements after dilution of the suspensions in 10 mM KCl. 
Phospholipid phosphorous was assessed in each liposome preparation by phosphate assay after 
destruction with perchloric acid [46]. The amount of encapsulated DSF was determined by HPLC. 
Ten μl of liposomal suspension were diluted in 30 μl of methanol, sonicated, vortexed and 
centrifuged for 5 minutes at 6000 x g. Then, the clear supernatant was filtered with 0.45 µm PTFE 
filters and analyzed by HPLC. The column was eluted with methanol/water (80:20 v/v) flow rate 
0.8 ml/min. Detection was performed by UV adsorption measurement at 275 nm. Peak heights were 
recorded and processed on a CBM-10A Shimadzu interface. The drug concentration was calculated 
from standard curves. The assay was linear over the tested concentration range (5-50 µg). Each 
sample was analyzed in triplicate.  
The amount of Cu(DDC)2 incorporated into liposomes was determined by UV-VIS 
spectrophotometer: 20 μl of liposomal suspension were diluted in 480 μl of DMSO, sonicated, 
vortexed and centrifuged for 5 minutes at 6000 x g and the supernatant was analyzed at 435 nm. 
Each sample was analyzed in triplicate. Liposomal preparations were analyzed for physical stability 
in the storage conditions (4 °C) evaluating diameter, zeta potential and drug leakage at different 
time intervals. Drug leakage was determined by submitting 200 µl of liposomes to purification 
through chromatography on Sepharose CL-4B columns, eluting with HEPES buffer for DSF or SH 
buffer for Cu(DDC)2 and re-analyzing for drug and phospholipid content as described above. A 
change in content was interpreted as an indication of liposome instability. 
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2.5.1. Differential Scanning Calorimetry (DSC) 
DSC analysis was performed on hydrated samples. About 20 mg of accurately weighted suspension 
samples were introduced into a 40 µl aluminum pan and analyzed. DSC runs were conducted from 
25 °C to 80 °C at a rate of 10 °C/min under constant nitrogen stream (40 ml/min). The main 
transition temperature (Tm) was determined as the onset temperature of the highest peak. 
Calibration was achieved using indium (Tm = 156.83 °C) and n-decane (Tm = -29.6 °C). 
 
2.5.2. Cryogenic Transmission Electron Microscopy (cryo-TEM)  
Empty and Cu(DDC)2 loaded liposomes (30 mg/ml) were diluted 5X in SH buffer and 5 μl of 
solution were deposited onto copper grids covered with Lacey carbon film. Excess of solution was 
blotted off for 5 or 7 seconds using filter paper and the grids were subsequently frozen in liquid 
ethane using a Leica EM GP automatic system (Leica, Austria) under 90% humidity atmosphere. 
 
2.6. In vitro cell studies 
 
2.6.1. Cell lines 
The human Panc1 pancreatic adenocarcinoma cell line was grown in RPMI 1640 supplemented 
with 10% FBS, 2 mM glutamine, and 50 µg/ml gentamicin sulfate (Gibco, Thermo Fisher 
Scientific, Milan, Italy) at 37 °C with 5% CO2. Panc1 CSCs were generated as previously described 
[8] and cultured in CSC medium, [DMEM/F-12 (US biological Life Sciences) supplemented with 
1g/l glucose, B27 (Gibco, Thermo Fisher Scientific), 1 µg/ml fungizone (Gibco, Thermo Fisher 
Scientific), 1% penicillin/streptomycin (Gibco, Thermo Fisher Scientific), 5 µg/ml heparin (Sigma-
Aldrich), 20 ng/ml EGF (epidermal growth factor, Peprotech, London, UK), and 20 ng/ml FGF 
(fibroblast growth factor, Peprotech)] at 37 °C with 5% CO2. 
 
2.6.2. In vitro cytotoxicity assay 
Panc1 and Panc1 CSCs were plated in 96-well cell culture plates. Viable cells were counted by 
Trypan Blue dye exclusion and 7x10
3
 cells were seeded in each well. After 24 hours both cell lines 
were treated with a range of concentrations from 0.05 to 100 M of DSF, Zn(DDC)2, Fe(DDC)2 and 
Cu(DDC)2 or liposomes (LipoDSF-5%PEG, LipoCu(DDC)2-5%PEG, LipoCu(DDC)2-5%HA4800, 
LipoCu(DDC)2-5%HA17000, LipoCu(DDC)2-2%PEG-3%HA4800, and LipoCu(DDC)2-2%PEG-
3%HA17000). Cell viability was evaluated using resazurin Cell Viability Assay Kit (Immunological 
Science, Rome, Italy), which is an indicator of cell viability by converting resazurin, a non-
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fluorescent dye, to resorufin, a highly red fluorescent dye, in response to chemical reduction of 
growth medium due to cell growth. Sixty µl of resazurin solution (10 µl of resazurin and 50 µl of 
fresh medium) were added in each well. After 1 hour, the fluorescent signal was monitored using 
535 nm excitation wavelength and 590 nm emission wavelength. The fluorescent signal generated 
from the assay is proportional to the number of living cells in the well. Three independent 
experiments were performed for each condition and cell viability was reported as the percentage 
relative to control.  
 
2.6.3. ROS analyses 
The non-fluorescent diacetylated 2,7-dichlorofluorescein (DCF-DA) probe (Sigma-Aldrich), which 
becomes highly fluorescent upon oxidation, was used to evaluate intracellular ROS production. 
Briefly, cells were plated in 96-well plates (1x10
4
 cells/well) and, the day after, were treated with 
the various compounds at the indicated concentrations for 24 hours. At the end of the various 
treatments, the cells were incubated in culture medium with 10 µM DCF-DA for 15 min at 37 °C. 
The cells were washed with PBS and the DCF fluorescence was measured by using a multimode 
plate reader (Ex485 nm and Em535 nm) (GENios Pro, Tecan). The values were normalized on cell 
number by using trypan blue solution. 
 
2.6.4. Glutathione analyses 
Metabolites were extracted as previously reported [47]. Analyses were performed with an Ultimate 
3000 Rapid Resolution HPLC system (LC Packings, DIONEX, Sunnyvale, CA) and an electrospray 
hybrid quadrupole time-of-flight instrument MicroTOF-Q (Bruker-Daltonik, Bremen, Germany) 
equipped with an ESI-ion source. The procedures and technical settings used were consistent with 
our previous investigation [47]. Because calibration of the mass analyzer is essential in order to 
maintain a high level of mass accuracy, instrument calibration was performed externally every day 
with a sodium formate solution consisting of 10 mM sodium hydroxide in 50% isopropanol: water, 
0.1% formic acid. Automated internal mass scale calibration was performed through direct 
automated injection of the calibration solution at the beginning and at the end of each run by a 6-
port divert-valve. Metabolite data elaboration was performed through MAVEN.52; mass 
spectrometry chromatograms were elaborated for peak alignment, matching and comparison of 
parent and fragment ions, and tentative metabolite identification (within a 10 ppm mass-deviation 
range between observed and expected results against the imported KEGG database). 
 
2.6.5. Primary human pancreatic cancer cells  
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Human PDAC tissues were obtained with written informed consent from all patients. Primary 
cultures of freshly retrieved cancer cells were obtained from patients with advanced pancreatic 
cancer (C75, C76, C102) or from in vivo patient-derived xenografts (PDX) (A6L, 12556). Tumors 
were minced, enzymatically digested with collagenase (STEMCELL Technologies, Vancouver, 
Canada) and, after centrifugation, cell pellets were resuspended and cultured in RPMI1640 
supplemented with 10% FBS and 50 U/ml penicillin–streptomycin. PDX-derived tumor cells were 
cultured until passage 10 [48].  
A6L, 12556, C75, C76 and C102 cells were plated in 96-well cell culture plates. Viable cells were 
counted by Trypan Blue dye exclusion and 3x10
3
 cells were seeded in each well and cultured as 
spheres with DMEM:F12 supplemented with B27 and bFGF in anchorage independent suspension 
conditions for 3 days (first generation spheres). First generation tumor spheres were harvested using 
a 40 µm cell strainer, dissociated into single cells by trypsinization, and then re-cultured for 
additional 7 days (second generation spheres). After 3 days, spheres were treated with 0.1 M of 
DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG or LipoCu(DDC)2-2%PEG-3%HA17000 for 24 hours. Cell 
viability was evaluated using resazurin Cell Viability Assay Kit as described in section 2.6.2. Three 
independent experiments were performed for each condition and cell viability was reported as the 
percentage relative to control.  
 
2.6.6. Sphere formation assay 
Pancreatic cancer spheres of first and second generation were obtained by culturing primary 
pancreatic cancer cells as described in section 2.6.5. Ten thousands cells were seeded in each well 
in 24-well cell culture plate and incubated for 3 days. Then, first and second generation spheres 
were treated with 0.1 µM of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG or LipoCu(DDC)2-2%PEG-
3%HA17000 for 4 days. After treatment, a CASY Cell Counter (Roche Applied Sciences, Mannheim, 
Germany) was used to quantify spheres with a diameter > 40 µm. Each condition was performed in 
triplicate. 
 
2.6.7. Statistical analysis 
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad Prism 5 (GraphPad Software) 
and used for multiple-group comparison. Student's t-test was used for individual group comparison. 
P-values < 0.05, 0.01, 0.001 were indicated as *, **, ***, respectively. 
 
3. Results and discussion 
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3.1. Synthesis and cytotoxic activity of DDC-metal complexes  
 
As widely reported in the literature, DSF and dithiocarbamates are able to form stable complexes 
with metals such as copper, zinc, gold, and iron [49]. The resulting complexes show the ability to 
inhibit proteasome, metalloproteinases and to induce ROS production [24, 27, 50].  
In this work, complexes between DSF active metabolite DDC and zinc, iron and copper were 
prepared by mixing aqueous solution of the corresponding salts with DDC. The complexation was 
instantaneous and visible because of the formation of a considerable amount of precipitate. MS 
analysis confirmed the formation of the complexes revealing that two molecules of DDC were 
complexed with one atom of metal and indicating that the resulting structure was the same that 
could be obtained in the reaction between DSF and metals. We decided to use DDC instead of DSF 
for two reasons. First, because the purification process of the complexes was easier due to the water 
solubility of both reagents, DDC and metal salts, which were easily separated from the product by 
water washing. Second, because the method used to prepare liposomes containing Cu(DDC)2 
involved the use of DDC to obtain the formation of the complex inside the liposomes (see below). 
The antitumor activity of DDC/metal complexes was evaluated, at doses ranging from 0 to 100 M, 
on Panc1 parental cell line or the derived Panc1 CSCs. Cu(DDC)2 was significantly more 
efficacious than DSF, Zn(DDC)2 and Fe(DDC)2, inducing a concentration-dependent reduction of 
growth on both cell lines (Fig. 1, Table 1). Treatments of 72 hours with Cu(DDC)2 showed a greater 
inhibition of cell growth resulting in a total mortality even at low doses both in Panc1 cells and 
Panc1 CSCs (Fig. 1 B and D), with IC50 values of 0.68±0.16 and 0.35±0.03, respectively (Table 1). 
These results demonstrate that Cu(DDC)2 possesses the strongest antitumor activity in our cell 
models. For this reason and for its well documented anticancer activity [15, 19], Cu(DDC)2 was 
chosen for the following experiments. 
 
3.2. Preparation and characterization of liposomes 
 
3.2.1. DSF containing liposomes 
This preparation was especially elaborated to find the suitable phospholipidic mixture able to 
prevent drug leakage. In particular, formulations containing L-α-phosphatidylcholine or 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine with different amounts of CHOL (from 10% to 40%) 
were not stable and after 24 hours at 4 °C the total amount of encapsulated DSF was released from 
liposomes. For this reason, a “rigid” formulation composed of a phospholipid with a high transition 
temperature (DSPC) and 40% of CHOL was prepared in order to prevent rapid drug leakage. These 
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liposomes displayed a mean size of about 165 nm, low polydispersity index (PDI<0.1) and negative 
zeta potential value. Despite favorable characteristics of DSF, i.e. low molecular weight and 
lipophilic structure, its entrapment efficiency (EE) was around 65% (Table 2) corresponding to a 
final drug loading of 0.8% (mg of drug per mg of phospholipids). However, it is important to note 
that to obtain a stable liposome formulation, the amount of CHOL was increased to 40% and this 
probably hampered the complete encapsulation of DSF into the phospholipid bilayer. 
Liposome stability was evaluated in HEPES buffer at 4 °C by measuring, at various times, mean 
diameter, zeta potential value, drug leakage and phospholipid content. Liposomes were stable for 35 
days maintaining 80% of their initial drug content. Over this period, no appreciable size change 
(<10%) and liposome precipitation were observed as well as no change in zeta potential. 
 
3.2.2. Cu(DDC)2 containing liposomes  
Cu(DDC)2 containing liposomes were prepared by using the method described by Wehbe et al. [45, 
51], which provides the formation of the active Cu(DDC)2 complex inside the preformed liposomes 
and its consequent precipitation within the aqueous core in a single step. The method is based on the 
different membrane permeability of DDC compared to the complex. Indeed, DDC is water soluble 
and membrane permeable while the copper complex is water insoluble and membrane impermeable. 
The lipid film composed of DSPC, CHOL and mPEG-DSPE in 55:40:5 molar ratio was hydrated 
with a solution of CuCl2 and incubated at 60 °C, then the CuCl2 was eliminated by gel filtration and 
liposomes containing CuCl2 in the aqueous core were obtained. Then, DDC was added to the 
liposomes and incubated at room temperature and a drastic color change from light blue to brown 
was observed indicating the occurred complex formation. Finally, non encapsulated Cu(DDC)2 was 
removed by gel filtration. 
In order to prepare hyaluronic acid decorated liposomes, the conjugates HA4800-DPPE or HA17000-
DPPE, in molar ratio of 3 or 5%, were added during the hydration phase of lipid film. In this way, 
the phospholipidic chain was incorporated into the liposome membrane, while the HA was exposed 
toward the aqueous phase. Liposomes displayed a dimensional range from about 165 nm to 225 nm 
and the particle size of the HA-liposomes tended to increase with the increase of polymer MW. The 
PDI was low for all the formulations (< 0.2) and the zeta potential value was negative and lower for 
HA-liposomes compared to the plain ones, due to the carboxylic negative residues of HA. In 
particular, the negative charge increased with the increase of HA MW (Table 2). These data 
confirmed the presence of HA on the surface of the liposomes. 
The formulations showed a good EE (Table 2), which was similar for plain liposomes and for 
liposomes decorated with HA4800-DPPE or HA17000-DPPE, indicating that the method of 
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encapsulation ensured high drug loading and that the introduction of the HA-DPPE conjugates did 
not affect the Cu(DDC)2 encapsulation. The final drug loading was about 4% for all the liposomal 
formulations. All formulations were stable at 4 °C for at least 35 days, as shown by the unchanged 
values of drug leakage, size and zeta potential over this period. 
 
3.2.3. Differential Scanning Calorimetry (DSC) 
In order to evaluate the interactions between DSF and the liposome membrane, a DSC analysis was 
performed (Fig. 2). The thermogram of pure DSPC presented the main transition, related to the 
passage from the ripple gel phase (Pβ) to the lamellar liquid–crystalline phase (Lα), at Tonset 54.3 
°C. In the presence of mPEG-DSPE, no significant changes in the transition temperature were 
observed (Tonset 54.0 °C), but a slight enlargement of the peak appeared. When DSF was added, the 
main transition was shifted to lower temperatures, Tonset 52.8 °C, and a substantial broadening of 
melting temperature peaks was observed, indicating that DSF interacts with the liposome bilayer 
through hydrophobic interactions by perturbing the phase transition behavior. 
 
3.2.4. Cryogenic Transmission Electron Microscopy (cryo-TEM) 
The morphology of Cu(DDC)2 liposomes was evaluated by cryo-TEM analysis. In Fig. 3, the 
images relative to the empty (A) or loaded non-decorated formulations (Fig. 3B-F) are shown. It is 
possible to note the presence of unilamellar and multilamellar liposomes, probably due to the 
limited number of extrusion cycles performed. Liposomes showed the typical spherical shape or, in 
few cases, elongated shape due to the pressure exerted by ice layer, and presented slightly different 
sizes. The most interesting observation was the presence of needle-shaped structures (Fig. 3 C-F) 
representing stacked Cu(DDC)2 complexes precipitated inside the aqueous core of liposomes in the 
form of crystals. 
 
3.3 Studies on cells 
 
3.3.1 Cu(DDC)2 containing liposomes possess a strong anti-proliferative activity on Panc1 cells 
and Panc1 CSCs  
The liposomal formulation containing DSF (LipoDSF-5%PEG) was significantly more active than 
free DSF, only after 72 hours of treatment, in both cell lines, as shown by the IC50 values in Table 1 
and by the cell growth curve in Supplementary material Fig. S1. Moreover, Panc1 CSCs were more 
sensitive than Panc1 to LipoDSF-5%PEG treatment at both incubation times (Table 1). Loading of 
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Cu(DDC)2 into the liposomes strongly increased the anti-proliferative effect of Cu(DDC)2. As 
reported in Fig. 4, LipoCu(DDC)2-5%PEG showed a higher anti-proliferative activity than 
Cu(DDC)2 in Panc1 and Panc1 CSCs, resulting in a concentration dose-dependent reduction of cell 
growth and lower IC50 values (Table 1). To investigate the targeting ability of HA towards CD44-
expressing tumor cells, the anti-proliferative effect of Cu(DDC)2 loaded in liposomes coated with 
HA with two different MW and/or with different percentage of PEG was evaluated. Liposomal 
formulations containing either PEG or HA determined a similar inhibition of cell proliferation, 
whereas the presence of both PEG and HA17000 further increased the anti-proliferative activity of 
Cu(DDC)2 at 24 hours (Fig. 4 and Table 1), in both cell lines. Furthermore, after 72 hours of 
treatment, Panc1 CSCs were more sensitive to liposome formulations with HA17000 and/or PEG 
compared to Panc1 cells (Table 1). Interestingly, when the anti-proliferative effect was examined at 
a concentration of the Cu(DDC)2 as low as 0.1 M, Panc1 CSCs were highly sensitive to liposomal 
formulations, with HA coated liposomes being more active than the plain ones, while Panc1 cells 
were completely resistant (Fig. 5). Altogether, these results demonstrate that liposomes coated with 
2%PEG and 3% HA17000 are the most effective tested formulation on both cell lines, with a higher 
efficacy on CSCs markedly at low Cu(DDC)2 concentration, suggesting that it could be used in 
PDAC therapy.  
 
3.3.2. Reactive oxygen species (ROS) are responsible for the higher anti-proliferative activity of 
LipoCu(DDC)2-2%PEG-3%HA17000 on Panc1 CSCs compared to parental cells 
Cu(DDC)2 has been described as an ionophore complex able to induce a copper-mediated ROS 
increase that can promote a mitochondrial-mediated cell death program [21]. To verify whether 
ROS were responsible for the higher anti-proliferative activity of LipoCu(DDC)2-2%PEG-
3%HA17000 on Panc1 CSCs compared to parental cells, we measured ROS production on Panc1 cells 
and Panc1 CSCs at the constitutive level and after treatment with LipoCu(DDC)2-2%PEG-
3%HA17000 containing 0.1 M of Cu(DDC)2. In parallel, we determined the effect of ROS 
neutralization on cell growth. Figure 6 shows that constitutive ROS levels were significantly higher 
in CSCs compared to parental cells (Fig. 6 A) and they increased after treatment only in CSCs (Fig. 
6 B). Neutralization of ROS with N-acetyl-L-cysteine (NAC) almost completely recovered cell 
viability (Fig. 6 C), indicating that ROS play a major role in CSC growth inhibition by 
LipoCu(DDC)2-2%PEG-3%HA17000.  
The observation that constitutive ROS levels were higher in Panc1 CSCs compared to parental cells 
prompted us to investigate the cellular status of GSH/glutathione disulphide, the major redox couple 
in animal cells. Figure 6 D indicates that the ratio GSH/GSSG is lower in Panc1 CSCs, consistently 
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with the higher amount of ROS compared to parental cells. This result strongly suggests that Panc1 
CSCs are more susceptible to the oxidative stress induced by Cu(DDC)2 probably because of an 
alteration of their metabolism leading to increased ROS and the consequential increased 
consumption of GSH. Indeed, we have recently published that Panc1 CSCs display, compared to 
Panc1 parental cells, a more glycolytic phenotype [47], which is known to maintain a high non-
toxic oxidative stress in cancer cells [52].  
 
3.3.3. Cu(DDC)2 containing liposomes possess a strong anti-proliferative activity on cells derived 
from PDAC patients 
To evaluate whether the liposome formulations were active also on a cellular context clinically 
relevant, we tested their anti-proliferative activity in comparison to DSF and Cu(DDC)2 on 
pancreatic cancer cells directly obtained from patients affected by PDAC. The primary cells 12556, 
A6L, C75, C76, and C102 were cultured as spheres, as described in Materials and Methods, and 
treated with 0.1 µM of the formulations mentioned above. Cell viability was evaluated after 24 
hours of treatment. As shown in Fig. 7, the liposome formulations containing Cu(DDC)2 were more 
effective than free compounds on first generation spheres and even more on second generation 
spheres. These data are particularly interesting since they show a strong anti-proliferative effect of 
Cu(DDC)2 containing liposomes on cells derived from PDAC patients having stem like features. 
Furthermore, they open the way to the clinical use of Cu(DDC)2 liposomal formulations due to their 
suitability for intravenous administration.  
 
3.4. Effect of DSF and DSF containing liposomes on sphere formation capability 
 
In the context of CSC features, the sphere formation capability is generally studied in vitro and used 
to identify new ways for targeting CSCs [48]. A specific method for culturing primary human 
pancreatic cancer cells from tissues resected during surgery was used in order to obtain tumor 
spheres of first or second generation. In Fig. 8, the effect of DSF, Cu(DDC)2, LipoCu(DDC)2-
5%PEG and LipoCu(DDC)2-2%PEG-3%HA17000 on the in vitro sphere formation capability is 
shown. Liposome formulations at 0.1 µM of Cu(DDC)2 decreased the number of first generation 
spheres, while DSF and Cu(DDC)2 treatment slightly affected or did not affect sphere number. Also 
the cellular morphology was affected by liposome formulation treatment (Supplementary material 
Fig. S2), as shown by the loss of the typical shape of the spheres, which appeared similar to small 
cell aggregates. The first generation spheres were subsequently passaged into second generation 
spheres and also the formation of these spheres was drastically reduced (Fig. 8). Thus, our data 
%cell viability  
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demonstrate a significant inhibitory effect of liposome formulations on the capacity of primary 
pancreatic cancer stem like cells to form spheres, which is a typical feature of these cells.  
 
 
Conclusions 
The results described in this paper are of great relevance from clinical point of view since, for the 
first time to our knowledge, they open the way to consider liposomes decorated with HA and 
encapsulating the potent anti-proliferative Cu(DDC)2 complex as a potent therapeutic tool against 
PDAC. Indeed, it has been widely reported that PDAC initiation, growth, metastasis and resistance 
to therapy are driven by CSCs and our impressive data on primary cells with a stem like phenotype 
directly derived from PDAC patients show the high capacity of Cu(DDC)2 liposomal formulations 
to inhibit the proliferation and the sphere forming capability of these cells.  
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Figure captions 
 
Fig. 1: Effect of DSF, Zn(DDC)2, Fe(DDC)2, Cu(DDC)2 on Panc1 parental (P) (A and B) and 
Panc1 CSCs (C and D) cell growth. Cells were seeded in 96-well plates and treated after 24 hours 
with increasing concentrations of DSF formulations for 24 hours (A and C) or 72 hours (B and D). 
Cell growth was determined using the resazurin cell viability assay. Values are the means ± SEM of 
three independent experiments each performed in triplicate. Statistical analysis: DSF or Zn(DDC)2 
or Fe(DDC)2 versus Cu(DDC)2, * p < 0.05. 
Fig. 2: DSC thermograms of pure DSPC, DSPC + mPEG-DSPE and DSPC+mPEG-DSPE+DSF. 
Fig. 3: Cryo-TEM images of empty liposomes (A) and Cu(DDC)2 loaded liposomes (B-F). 
Fig. 4: Effect of Cu(DDC)2 and of liposome formulations LipoCu(DDC)2-5%PEG, LipoCu(DDC)2-
5%HA4800, LipoCu(DDC)2-5%HA17000, LipoCu(DDC)2-2%PEG-3%HA4800, LipoCu(DDC)2-
2%PEG-3%HA17000 on Panc1 parental (P) (A and B) and Panc1 CSCs (C and D) cell growth. Cells 
were seeded in 96-well plates and treated after 24 hours with increasing concentrations of 
Cu(DDC)2 formulations for 24 hours (A and C) or 72 hours (B and D). Cell growth was determined 
using the resazurin cell viability assay. Values are the means ± SEM of three independent 
experiments each performed in triplicate. Statistical analysis: liposome formulations versus 
Cu(DDC)2, * p < 0.05. 
Fig. 5: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and LipoCu(DDC)2-2%PEG-3%HA17000 
on Panc1 parental (P) and Panc1 CSCs cell growth. Cells were treated with 0.1 M of compounds 
for 24 hours (A) or 72 hours (B). Statistical analysis: CTRL versus treated, or as indicated in figure 
* p < 0.05, ** p < 0.01, *** p < 0.001.  
Fig. 6: Analyses of intracellular ROS production on Panc1 parental cells and Panc1 CSCs at the 
constitutive level (A) and after treatment with LipoCu(DDC)2-2%PEG-3%HA17000 containing 0.1 
M of the active compound for 24 hours treatment (B). Effect of 5 mM NAC and/or 0.1 M 
LipoCu(DDC)2-2%PEG-3%HA17000 on Panc1 parental and Panc1 CSC cell growth after 24 hours 
treatment (C). Absolute glutathione quantification (arbitrary ion counts) in Panc1 cells (P; white 
histogram) and Panc1 CSCs (black histogram) (D). Values are presented as mean ± SEM. Statistical 
analysis: P cells versus CSCs, or as indicated in figure * p < 0.05, ** p < 0.01. 
Fig. 7: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and LipoCu(DDC)2-2%PEG-3%HA17000 
on cell growth of primary PDAC cells (12556, A6L, C75, C76, C102) cultured as first and second 
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generation spheres. Cells were treated with 0.1 M compounds for 24 hours. Cell growth was 
determined using the resazurin cell viability assay. Values are the means ± SEM of three 
independent experiments each performed in triplicate. Statistical analysis: CTRL versus treated, or 
as indicated in figure * p < 0.05, ** p < 0.01, *** p < 0.001. 
Fig. 8: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and LipoCu(DDC)2-2%PEG-3%HA17000 
on 12556, C75, C76, and C102 spheres formation capability. Cells were seeded in 24-well plates for 
first or second generation spheres and treated after 3 days with 0.1 M compounds for 4 days. 
Spheres number was determined through sphere formation assay performed by CASY Counter and 
reported as spheres of 40-80 m, 80-120 m and >120 m of diameter. Statistical analysis: CTRL 
versus treated, or as indicated in figure * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
